Efgartigimod SC is the first-approved FcRn blocker globally and is marketed as VYVGART® Hytrulo in the United States and China for the treatment of generalized myasthenia gravis (gMG) and chronic ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

GSA Capital Partners LLP lifted its stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 66.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 24,634 shares of the ...

Jason Eagle was enjoying his time in the U.S. Navy when, about a decade ago, he realized something was off. He started to experience numbness in his leg, lost sensation in his hands and developed ...

Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of Dianthus Therapeutics in a research ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

The company’s initiation of a pivotal Phase 3 study for DNTH103 in treating chronic inflammatory demyelinating polyneuropathy (CIDP) is a significant step, with the potential to establish DNTH103 as a ...

慢性炎性脱髓鞘性多发性神经根神经病（CIDP）是一种罕见的由免疫介导的脱髓鞘性周围神经病1。CIDP患者会经历一系列的行动和感觉问题，包括从坐姿站起来困难、疼痛和疲劳、经常绊倒或摔倒。随着疾病进展，许多患者需依赖轮椅且无法工作，对患者造成严重的疾病负 ...

Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...